

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues were raised at scoping.

Previous evaluations for this condition have noted that visual impairment resulting from wet age-related macular degeneration is recognised as a disability under the Equality Act 2010. So, the population of this evaluation is considered a protected group under the Act.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will take into account that Port Delivery Platform with a customised formulation of ranibizumab would be used in people with visual impairment when formulating its recommendations.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

Approved by Principal Technical Adviser (name): Adam Brooke

Date: 29/01/2026